Investigations  ||| S:0 E:15 ||| NNS
on  ||| S:15 E:18 ||| IN
the  ||| S:18 E:22 ||| DT
antifatigue  ||| S:22 E:34 ||| NN
and  ||| S:34 E:38 ||| CC
antihypoxic  ||| S:38 E:50 ||| JJ
effects  ||| S:50 E:58 ||| NNS
of  ||| S:58 E:61 ||| IN
Paecilomyces  ||| S:61 E:74 ||| NNP
hepiali  ||| S:74 E:82 ||| FW
extract  ||| S:82 E:90 ||| FW
Paecilomyces  ||| S:90 E:103 ||| FW
hepiali ||| S:103 E:110 ||| FW
,  ||| S:110 E:112 ||| ,
one  ||| S:112 E:116 ||| CD
of  ||| S:116 E:119 ||| IN
the  ||| S:119 E:123 ||| DT
most  ||| S:123 E:128 ||| RBS
valuable  ||| S:128 E:137 ||| JJ
and  ||| S:137 E:141 ||| CC
effective  ||| S:141 E:151 ||| JJ
Chinese  ||| S:151 E:159 ||| JJ
medicinal  ||| S:159 E:169 ||| JJ
herbs ||| S:169 E:174 ||| NN
,  ||| S:174 E:176 ||| ,
possesses  ||| S:176 E:186 ||| VBZ
potential  ||| S:186 E:196 ||| JJ
antioxidant ||| S:196 E:207 ||| NN
,  ||| S:207 E:209 ||| ,
immunomodulatory ||| S:209 E:225 ||| NN
,  ||| S:225 E:227 ||| ,
antitumor  ||| S:227 E:237 ||| NN
and  ||| S:237 E:241 ||| CC
anti‑inflammatory  ||| S:241 E:259 ||| CD
properties ||| S:259 E:269 ||| NNS
.  ||| S:269 E:271 ||| .
The  ||| S:271 E:275 ||| DT
present  ||| S:275 E:283 ||| JJ
study  ||| S:283 E:289 ||| NN
aimed  ||| S:289 E:295 ||| VBN
to  ||| S:295 E:298 ||| TO
investigate  ||| S:298 E:310 ||| VB
the  ||| S:310 E:314 ||| DT
antifatigue  ||| S:314 E:326 ||| NN
and  ||| S:326 E:330 ||| CC
antihypoxic  ||| S:330 E:342 ||| JJ
effects  ||| S:342 E:350 ||| NNS
of  ||| S:350 E:353 ||| IN
Paecilomyces  ||| S:353 E:366 ||| NNP
hepiali  ||| S:366 E:374 ||| FW
extract  ||| S:374 E:382 ||| FW
( ||| S:382 E:383 ||| -LRB-
PHC ||| S:383 E:386 ||| NNP
)  ||| S:386 E:388 ||| -RRB-
in  ||| S:388 E:391 ||| IN
a  ||| S:391 E:393 ||| DT
mouse  ||| S:393 E:399 ||| NN
model ||| S:399 E:404 ||| NN
.  ||| S:404 E:406 ||| .
Using  ||| S:406 E:412 ||| VBG
a  ||| S:412 E:414 ||| DT
rotating  ||| S:414 E:423 ||| JJ
rod ||| S:423 E:426 ||| NN
,  ||| S:426 E:428 ||| ,
forced  ||| S:428 E:435 ||| VBN
swimming  ||| S:435 E:444 ||| NN
and  ||| S:444 E:448 ||| CC
running  ||| S:448 E:456 ||| VBG
assessment ||| S:456 E:466 ||| NN
,  ||| S:466 E:468 ||| ,
the  ||| S:468 E:472 ||| DT
antifatigue  ||| S:472 E:484 ||| JJ
activity  ||| S:484 E:493 ||| NN
of  ||| S:493 E:496 ||| IN
PHC  ||| S:496 E:500 ||| NNP
was  ||| S:500 E:504 ||| VBD
determined ||| S:504 E:514 ||| VBN
.  ||| S:514 E:516 ||| .
PHC  ||| S:516 E:520 ||| NNP
administration  ||| S:520 E:535 ||| NN
for  ||| S:535 E:539 ||| IN
7 days  ||| S:539 E:546 ||| NNP
had  ||| S:546 E:550 ||| VBD
no  ||| S:550 E:553 ||| DT
effect  ||| S:553 E:560 ||| NN
on  ||| S:560 E:563 ||| IN
mouse  ||| S:563 E:569 ||| NN
horizontal  ||| S:569 E:580 ||| NNS
or  ||| S:580 E:583 ||| CC
vertical  ||| S:583 E:592 ||| JJ
movement ||| S:592 E:600 ||| NN
,  ||| S:600 E:602 ||| ,
indicating  ||| S:602 E:613 ||| VBG
no  ||| S:613 E:616 ||| DT
neurotoxicity  ||| S:616 E:630 ||| NN
at  ||| S:630 E:633 ||| IN
the  ||| S:633 E:637 ||| DT
selected  ||| S:637 E:646 ||| JJ
doses  ||| S:646 E:652 ||| NNS
was  ||| S:652 E:656 ||| VBD
observed ||| S:656 E:664 ||| VBN
.  ||| S:664 E:666 ||| .
Using  ||| S:666 E:672 ||| VBG
a  ||| S:672 E:674 ||| DT
normobaric  ||| S:674 E:685 ||| JJ
hypoxia ||| S:685 E:692 ||| NN
,  ||| S:692 E:694 ||| ,
sodium  ||| S:694 E:701 ||| FW
nitrite  ||| S:701 E:709 ||| FW
toxicosis  ||| S:709 E:719 ||| FW
and  ||| S:719 E:723 ||| CC
acute  ||| S:723 E:729 ||| JJ
cerebral  ||| S:729 E:738 ||| JJ
ischemia  ||| S:738 E:747 ||| JJ
assessments ||| S:747 E:758 ||| NNS
,  ||| S:758 E:760 ||| ,
PHC  ||| S:760 E:764 ||| NNP
was  ||| S:764 E:768 ||| VBD
confirmed  ||| S:768 E:778 ||| VBN
to  ||| S:778 E:781 ||| TO
possess  ||| S:781 E:789 ||| VB
antihypoxic  ||| S:789 E:801 ||| JJ
effects ||| S:801 E:808 ||| NNS
.  ||| S:808 E:810 ||| .
PHC  ||| S:810 E:814 ||| NNP
treatment  ||| S:814 E:824 ||| NN
for  ||| S:824 E:828 ||| IN
7 days  ||| S:828 E:835 ||| NNP
significantly  ||| S:835 E:849 ||| RB
enhanced  ||| S:849 E:858 ||| VBN
the  ||| S:858 E:862 ||| DT
serum  ||| S:862 E:868 ||| NN
and  ||| S:868 E:872 ||| CC
liver  ||| S:872 E:878 ||| JJ
levels  ||| S:878 E:885 ||| NNS
of  ||| S:885 E:888 ||| IN
adenosine  ||| S:888 E:898 ||| JJ
triphosphate ||| S:898 E:910 ||| NN
,  ||| S:910 E:912 ||| ,
superoxide  ||| S:912 E:923 ||| JJ
dismutase  ||| S:923 E:933 ||| NN
and  ||| S:933 E:937 ||| CC
glutathione  ||| S:937 E:949 ||| JJ
peroxidase ||| S:949 E:959 ||| NN
,  ||| S:959 E:961 ||| ,
prior  ||| S:961 E:967 ||| RB
to  ||| S:967 E:970 ||| TO
and  ||| S:970 E:974 ||| CC
following  ||| S:974 E:984 ||| VBG
60 min  ||| S:984 E:991 ||| NN
of  ||| S:991 E:994 ||| IN
swimming ||| S:994 E:1002 ||| NN
.  ||| S:1002 E:1004 ||| .
The  ||| S:1004 E:1008 ||| DT
levels  ||| S:1008 E:1015 ||| NNS
of  ||| S:1015 E:1018 ||| IN
antioxidant‑associated  ||| S:1018 E:1041 ||| CD
proteins  ||| S:1041 E:1050 ||| NNS
in  ||| S:1050 E:1053 ||| IN
the  ||| S:1053 E:1057 ||| DT
livers  ||| S:1057 E:1064 ||| NN
of  ||| S:1064 E:1067 ||| IN
the  ||| S:1067 E:1071 ||| DT
mice  ||| S:1071 E:1076 ||| NNS
were  ||| S:1076 E:1081 ||| VBD
analyzed  ||| S:1081 E:1090 ||| VBN
using  ||| S:1090 E:1096 ||| VBG
western  ||| S:1096 E:1104 ||| JJ
blotting ||| S:1104 E:1112 ||| NN
.  ||| S:1112 E:1114 ||| .
PHC  ||| S:1114 E:1118 ||| NNP
effectively  ||| S:1118 E:1130 ||| RB
increased  ||| S:1130 E:1140 ||| VBD
the  ||| S:1140 E:1144 ||| DT
expression  ||| S:1144 E:1155 ||| NN
levels  ||| S:1155 E:1162 ||| NNS
of  ||| S:1162 E:1165 ||| IN
phosphorylated  ||| S:1165 E:1180 ||| NNS
( ||| S:1180 E:1181 ||| -LRB-
p ||| S:1181 E:1182 ||| LS
) ||| S:1182 E:1183 ||| -RRB-
‑5 ||| S:1183 E:1185 ||| NNP
' ||| S:1185 E:1186 ||| POS
‑monophosphate  ||| S:1186 E:1201 ||| NNP
( ||| S:1201 E:1202 ||| -LRB-
AMP ||| S:1202 E:1205 ||| NNP
) ||| S:1205 E:1206 ||| -RRB-
‑activated  ||| S:1206 E:1217 ||| FW
protein  ||| S:1217 E:1225 ||| FW
kinase  ||| S:1225 E:1232 ||| FW
( ||| S:1232 E:1233 ||| -LRB-
AMPK ||| S:1233 E:1237 ||| NNP
) ||| S:1237 E:1238 ||| -RRB-
,  ||| S:1238 E:1240 ||| ,
p‑protein  ||| S:1240 E:1250 ||| NNP
kinase B  ||| S:1250 E:1259 ||| NNP
( ||| S:1259 E:1260 ||| -LRB-
AKT ||| S:1260 E:1263 ||| NNP
)  ||| S:1263 E:1265 ||| -RRB-
and  ||| S:1265 E:1269 ||| CC
p‑mammalian  ||| S:1269 E:1281 ||| CD
target  ||| S:1281 E:1288 ||| NN
of  ||| S:1288 E:1291 ||| IN
rapamycin  ||| S:1291 E:1301 ||| NNS
( ||| S:1301 E:1302 ||| -LRB-
mTOR ||| S:1302 E:1306 ||| NNP
) ||| S:1306 E:1307 ||| -RRB-
.  ||| S:1307 E:1309 ||| .
The  ||| S:1309 E:1313 ||| DT
results  ||| S:1313 E:1321 ||| NNS
of  ||| S:1321 E:1324 ||| IN
the  ||| S:1324 E:1328 ||| DT
present  ||| S:1328 E:1336 ||| JJ
study  ||| S:1336 E:1342 ||| NN
demonstrated  ||| S:1342 E:1355 ||| VBN
that  ||| S:1355 E:1360 ||| IN
PHC  ||| S:1360 E:1364 ||| NNP
efficiently  ||| S:1364 E:1376 ||| RB
enhanced  ||| S:1376 E:1385 ||| JJ
endurance  ||| S:1385 E:1395 ||| NN
from  ||| S:1395 E:1400 ||| IN
fatigue  ||| S:1400 E:1408 ||| NN
and  ||| S:1408 E:1412 ||| CC
had  ||| S:1412 E:1416 ||| VBD
antihypoxic  ||| S:1416 E:1428 ||| JJ
effects  ||| S:1428 E:1436 ||| NNS
through  ||| S:1436 E:1444 ||| IN
elevation  ||| S:1444 E:1454 ||| NN
of  ||| S:1454 E:1457 ||| IN
the  ||| S:1457 E:1461 ||| DT
antioxidant  ||| S:1461 E:1473 ||| JJ
capacity  ||| S:1473 E:1482 ||| NN
in  ||| S:1482 E:1485 ||| IN
the  ||| S:1485 E:1489 ||| DT
serum  ||| S:1489 E:1495 ||| NN
and  ||| S:1495 E:1499 ||| CC
liver ||| S:1499 E:1504 ||| NN
,  ||| S:1504 E:1506 ||| ,
at  ||| S:1506 E:1509 ||| IN
least  ||| S:1509 E:1515 ||| JJS
in  ||| S:1515 E:1518 ||| IN
part  ||| S:1518 E:1523 ||| NN
through  ||| S:1523 E:1531 ||| IN
the  ||| S:1531 E:1535 ||| DT
AMPK  ||| S:1535 E:1540 ||| NNP
and  ||| S:1540 E:1544 ||| CC
AKT ||| S:1544 E:1547 ||| NNP
/ ||| S:1547 E:1548 ||| NNP
mTOR  ||| S:1548 E:1553 ||| JJ
pathways ||| S:1553 E:1561 ||| NN
.  ||| S:1561 E:1563 ||| .
These  ||| S:1563 E:1569 ||| DT
results  ||| S:1569 E:1577 ||| NNS
indicate  ||| S:1577 E:1586 ||| VBP
the  ||| S:1586 E:1590 ||| DT
potential  ||| S:1590 E:1600 ||| NN
of  ||| S:1600 E:1603 ||| IN
this  ||| S:1603 E:1608 ||| DT
natural  ||| S:1608 E:1616 ||| JJ
product  ||| S:1616 E:1624 ||| NN
as  ||| S:1624 E:1627 ||| IN
an  ||| S:1627 E:1630 ||| DT
antioxidant  ||| S:1630 E:1642 ||| NN
in  ||| S:1642 E:1645 ||| IN
the  ||| S:1645 E:1649 ||| DT
treatment  ||| S:1649 E:1659 ||| NN
of  ||| S:1659 E:1662 ||| IN
fatigue ||| S:1662 E:1669 ||| NN
,  ||| S:1669 E:1671 ||| ,
hypoxia  ||| S:1671 E:1679 ||| NN
and  ||| S:1679 E:1683 ||| CC
their  ||| S:1683 E:1689 ||| PRP$
associated  ||| S:1689 E:1700 ||| JJ
diseases ||| S:1700 E:1708 ||| NNS
.  ||| S:1708 E:1710 ||| .
